Kristen Nader
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Kristen Nader has a total of 98 co-authors. Here are the top co-authors by number of shared publications:
- Tero Aittokallio
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
42 shared publications - Aleksandr Ianevski
Institute for Molecular Medicine Finland (FIMM), HiLIFE, University of Helsinki, Helsinki, Finland
40 shared publications - Krister Wennerberg
Biotech Research and Innovation Center, University of Copenhagen, Copenhagen, Denmark
38 shared publications - Markus Vähä-Koskela
Institute for Molecular Medicine Finland - FIMM, Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
38 shared publications - Anil Kumar Giri
Institute for Molecular Medicine Finland (FIMM), Helsinki Institute of Life Science, University of Helsinki, Helsinki, Finland
37 shared publications - Caroline A. Heckman
University of Helsinki
37 shared publications
Latest Publications
- Open Access
Improving reproducibility in pharmacogenomic screens through cross-study benchmarking
Drug-response measurements across pre-clinical pharmacogenomic studies remain poorly correlated, which limits biomarker discovery, precision oncology, and predictive modelling. The drivers of this inconsistency have been debated but not yet resolved. By integrating 15 pharmacogenomic studies encompassing 760 small-molecule compounds, 1,111 cell models, and 9.8 million dose-response measurements, we demonstrate that dose-response metric is the strongest driver of inconsistency, followed by experimental factors, such as treatment duration, plate format, and viability readout; in contrast, cell line molecular features contribute only minimally to reproducibility. Among drug classes, hormone therapies and PARP inhibitors show the highest concordance, whereas antimetabolites, topoisomerase inhibitors, and mitotic inhibitors exhibit substantial response variability across studies. To improve consistency, we developed a Drug Response Score (DRS), a proximity-weighted measure that emphasize pharmacologically informative concentrations near IC 50 , and we demonstrate in systematic benchmarking how DRS markedly improved cross-dataset concordance. Applications to patient-derived neuroblastoma organoids and leukemia patients’ primary cells demonstrate that DRS improves replicate-level consistency in patients’ drug-response profiles. To improve reproducible pharmacogenomic studies, we make openly available an integrated Drug Response Resource (iDRR, https://aittokallio.group/iDRR/ ), a standardized 15-dataset portal that supports robust biomarker discovery and cross-study benchmarking.
Open AccessImproving reproducibility in pharmacogenomic screens through cross-study benchmarking
Drug-response measurements across pre-clinical pharmacogenomic studies remain poorly correlated, which limits biomarker discovery, precision oncology, and predictive modelling. The drivers of this inconsistency have been debated but not yet resolved. By integrating 15 pharmacogenomic studies encompassing 760 small-molecule compounds, 1,111 cell models, and 9.8 million dose-response measurements, we demonstrate that dose-response metric is the strongest driver of inconsistency, followed by experimental factors, such as treatment duration, plate format, and viability readout; in contrast, cell line molecular features contribute only minimally to reproducibility. Among drug classes, hormone therapies and PARP inhibitors show the highest concordance, whereas antimetabolites, topoisomerase inhibitors, and mitotic inhibitors exhibit substantial response variability across studies. To improve consistency, we developed a Drug Response Score (DRS), a proximity-weighted measure that emphasize pharmacologically informative concentrations near IC 50 , and we demonstrate in systematic benchmarking how DRS markedly improved cross-dataset concordance. Applications to patient-derived neuroblastoma organoids and leukemia patients’ primary cells demonstrate that DRS improves replicate-level consistency in patients’ drug-response profiles. To improve reproducible pharmacogenomic studies, we make openly available an integrated Drug Response Resource (iDRR, https://aittokallio.group/iDRR/ ), a standardized 15-dataset portal that supports robust biomarker discovery and cross-study benchmarking.
- Open Access
Human-supervised Agentic AI for Hypothesis Generation and Experimental Assistance in Drug Repurposing
Computational drug repurposing has focused largely on rapid hypothesis generation, yet real-world applications span a much broader lifecycle: suggesting drug candidates, designing experiments, analyzing assay data, and iteratively refining hypotheses. Here, we demonstrate that agentic AI can operate throughout this lifecycle. We developed RepurAgent, a hierarchical multi-agentic system comprising a supervisor agent and a planning agent that coordinates four specialized sub-agents (research, prediction, data, and report) with human in the loop, supported by episodic memory and retrieval-augmented generation. The system is grounded in repurposing-specific data, tools, and standard operating procedures developed within the REMEDi4ALL consortium. We validated RepurAgent across three scenarios spanning distinct stages within the repurposing lifecycle: in acute myeloid leukemia, a blinded expert evaluation indicated that RepurAgent produced substantially more candidates that were both novel and mechanistically credible than a vanilla LLM baseline; in a retrospective COVID-19 antiviral screen, RepurAgent acted as an adaptive experimental collaborator, prioritizing compounds with AUC-ROC up to 0.99 and average precision up to 0.91 without predefined thresholds and flagging confounders missed in manual review; and for multiple sulfatase deficiency, it prioritized 81 high-confidence candidates from 5159 compounds, which were further corroborated by domain experts. These results show that agentic AI can support work across the drug repurposing lifecycle, from hypothesis generation to experimental analysis. RepurAgent is open source and deployed at https://repuragent.serve.scilifelab.se/.
Open AccessHuman-supervised Agentic AI for Hypothesis Generation and Experimental Assistance in Drug Repurposing
Computational drug repurposing has focused largely on rapid hypothesis generation, yet real-world applications span a much broader lifecycle: suggesting drug candidates, designing experiments, analyzing assay data, and iteratively refining hypotheses. Here, we demonstrate that agentic AI can operate throughout this lifecycle. We developed RepurAgent, a hierarchical multi-agentic system comprising a supervisor agent and a planning agent that coordinates four specialized sub-agents (research, prediction, data, and report) with human in the loop, supported by episodic memory and retrieval-augmented generation. The system is grounded in repurposing-specific data, tools, and standard operating procedures developed within the REMEDi4ALL consortium. We validated RepurAgent across three scenarios spanning distinct stages within the repurposing lifecycle: in acute myeloid leukemia, a blinded expert evaluation indicated that RepurAgent produced substantially more candidates that were both novel and mechanistically credible than a vanilla LLM baseline; in a retrospective COVID-19 antiviral screen, RepurAgent acted as an adaptive experimental collaborator, prioritizing compounds with AUC-ROC up to 0.99 and average precision up to 0.91 without predefined thresholds and flagging confounders missed in manual review; and for multiple sulfatase deficiency, it prioritized 81 high-confidence candidates from 5159 compounds, which were further corroborated by domain experts. These results show that agentic AI can support work across the drug repurposing lifecycle, from hypothesis generation to experimental analysis. RepurAgent is open source and deployed at https://repuragent.serve.scilifelab.se/.
- Top Cited Papers
- 6 January 2026
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 23 (3) , 180-200
Discovery of predictive biomarkers for cancer therapy through computational approaches
Precision oncology involves the use of predictive biomarkers to personalize treatment. However, for most cancer therapeutics or combination regimens, effective biomarkers have been elusive. This challenge has fuelled efforts to interrogate increasingly diverse and complex clinical and molecular determinants of treatment response. Some molecular predictors have been identified (for example, based on analysis of transcriptomic or imaging data), although the limited reproducibility and robustness of many of these candidate biomarkers make them difficult to apply in clinical practice. Moreover, different types of predictor must often be combined to optimize treatment selection (for example, gene signatures plus patient characteristics). Computational methods, including machine learning and artificial intelligence approaches, provide opportunities to identify predictive patterns in both clinical data and preclinical datasets and to predict treatment response for individual patients. Such approaches also offer opportunities to predict the efficacy or synergy of drug combinations, for example, via extrapolation from correlations of monotherapy responses or by linking the cellular responses observed in preclinical drug screens with molecular and clinical data from patients. In this Review, we describe the application of computational methods to predictive biomarker discovery, including current progress, key challenges facing this field, and future opportunities.
- 6 January 2026
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 23 (3) , 180-200
Top Cited PapersDiscovery of predictive biomarkers for cancer therapy through computational approaches
Precision oncology involves the use of predictive biomarkers to personalize treatment. However, for most cancer therapeutics or combination regimens, effective biomarkers have been elusive. This challenge has fuelled efforts to interrogate increasingly diverse and complex clinical and molecular determinants of treatment response. Some molecular predictors have been identified (for example, based on analysis of transcriptomic or imaging data), although the limited reproducibility and robustness of many of these candidate biomarkers make them difficult to apply in clinical practice. Moreover, different types of predictor must often be combined to optimize treatment selection (for example, gene signatures plus patient characteristics). Computational methods, including machine learning and artificial intelligence approaches, provide opportunities to identify predictive patterns in both clinical data and preclinical datasets and to predict treatment response for individual patients. Such approaches also offer opportunities to predict the efficacy or synergy of drug combinations, for example, via extrapolation from correlations of monotherapy responses or by linking the cellular responses observed in preclinical drug screens with molecular and clinical data from patients. In this Review, we describe the application of computational methods to predictive biomarker discovery, including current progress, key challenges facing this field, and future opportunities.
- Open Access
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Multiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- 30 October 2025
- Published by American Association for Cancer Research (AACR) in Cancer Research
- Vol. 86 (2) , 295-309
Open AccessMultiomics Profiling of T-cell Leukemia and Lymphoma Enables Targeted Therapeutic Discovery
T-cell leukemias and lymphomas (TCL) form a heterogeneous group of rare and often aggressive malignancies. Because of the rarity and heterogeneity of TCL subtypes, clinical trials are challenging to conduct, making pharmacogenomic studies in cell line panels critical for the discovery of targeted therapeutics. The scarcity of data repositories with integrated multiomics and drug screening data hinders the preclinical evaluation of drug vulnerabilities and the identification of molecular markers predictive of responses to monotherapies and combinations. To address this gap, we conducted comprehensive pharmacogenomic profiling on a panel of 38 TCL cell lines, representing major clinical TCL subtypes to capture the molecular and phenotypic diversity. The TCL-38 multiomics data resource includes harmonized genetic, molecular, and epigenetic profiles, with comprehensive annotations and standardized drug response assessment of each cell line. This resource, together with machine learning predictions, was leveraged to identify TCL subtype–specific therapeutic vulnerabilities, including single-agent sensitivities and synergistic drug combinations, which were linked to genetic or epigenetic features as potential predictive biomarkers. This integrated and openly available resource (https://aittokallio.group/tcl38) could help advance the currently limited treatment options for patients with TCL. Significance: Integrated and harmonized multiomics analyses and drug screening across a heterogeneous panel of T-cell leukemias and lymphomas provide a resource to uncover drug targets and predictive biomarkers to improve patient outcomes.
- Open Access
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Supplementary Information from A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia
Supplementary Tables S1-S3 Supplementary Results Supplementary Discussion
- 25 July 2025
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Information from A Machine Learning–Based Strategy Predicts Selective and Synergistic Drug Combinations for Relapsed Acute Myeloid Leukemia
Supplementary Tables S1-S3 Supplementary Results Supplementary Discussion